Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23045Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Karavasilis, V. | en |
| dc.contributor.author | Malamou-Mitsi, V. | en |
| dc.contributor.author | Briasoulis, E. | en |
| dc.contributor.author | Tsanou, E. | en |
| dc.contributor.author | Kitsou, E. | en |
| dc.contributor.author | Pavlidis, N. | en |
| dc.date.accessioned | 2015-11-24T19:30:13Z | - |
| dc.date.available | 2015-11-24T19:30:13Z | - |
| dc.identifier.issn | 1048-891X | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23045 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adenocarcinoma/chemistry/*metabolism/*pathology/therapy | en |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Antigens, CD34/analysis/*biosynthesis | en |
| dc.subject | Antineoplastic Agents/therapeutic use | en |
| dc.subject | Female | en |
| dc.subject | Gynecologic Surgical Procedures | en |
| dc.subject | Humans | en |
| dc.subject | Microcirculation | en |
| dc.subject | Middle Aged | en |
| dc.subject | Neoplasm Staging | en |
| dc.subject | Neovascularization, Pathologic/*physiopathology | en |
| dc.subject | Ovarian Neoplasms/chemistry/*metabolism/*pathology/therapy | en |
| dc.subject | Platinum Compounds/therapeutic use | en |
| dc.subject | Thrombospondin 1/analysis/*biosynthesis | en |
| dc.subject | Vascular Endothelial Growth Factor A/analysis/*biosynthesis | en |
| dc.title | Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1111/j.1525-1438.2006.00316.x | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16515598 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/doi/10.1111/j.1525-1438.2006.00316.x/abstract | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | The aim of the study was to investigate angiogenesis in patients with advanced-stage ovarian carcinoma. We used paraffin-embedded tumor tissues from 33 patients diagnosed with FIGO III ovarian cancer who had optimal surgery and received platinum-based chemotherapy. The tissue expression of CD34, vascular endothelial growth factor (VEGF), and thrombospondin-1 (TSP-1) was assessed immunohistochemically. CD34 stained hot spot areas were used to evaluate tumor microvessel density (MVD). VEGF and TSP-1 were assessed by semiquantitative methods. The studied molecules were investigated for relationship with standard clinicopathologic parameters. MVD count was high: median value of 39, range 12-143 microvessels/mm2. VEGF was present in all cases and stained strong in 91%. Stroma staining for TSP-1 was weak in 79% of the cases, strong in 6%, and absent in five (15%). We did not find correlations between the three studied markers and histologic type or tumor grade. MVD score did not relate to VEGF or TSP-1. We only observed a trend toward a longer survival in patients with tumors expressing high TSP-1 (60 vs. 36 months, P= 0.1). Proangiogenetic factor VEGF is highly expressed in advanced-stage ovarian carcinomas. The findings of this study may offer support for considering VEGF-targeted therapeutics in ovarian cancer treatment research. | en |
| heal.journalName | Int J Gynecol Cancer | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
